For providers · Clinical resource
When to refer a patient with PMDD
Clinically reviewed by Josephine W. Hazeley, PMHNP-BC on · Last updated
Refer a patient with PMDD for psychiatric care when premenstrual mood symptoms impair function and need a treatment plan, when there is any premenstrual suicidality, when the diagnosis is uncertain, or when your first-line management has not controlled the symptoms. PMDD is treatable — SSRIs are first-line (ACOG CPG No. 7) — so the goal of a referral is to get the patient onto effective, cycle-targeted treatment, not simply to move her along. This guide is education for referring providers; it does not replace clinical judgment for an individual patient.
Not every premenstrual complaint needs psychiatry, and much of PMDD’s first-line care can begin in primary care or OB/GYN. The thresholds below are about where specialist psychiatric evaluation adds the most. This is a companion to the provider PMDD referral guide.
Refer when symptoms impair function
The threshold that separates PMDD from PMS is impairment, and impairment is the threshold for referral too. When premenstrual mood symptoms cost the patient work, relationships, or daily functioning — and prospective charting supports a PMDD pattern — a psychiatric evaluation can confirm the diagnosis and start cycle-targeted treatment. Roughly 5% to 8% of menstruating patients have premenstrual symptoms this severe (StatPearls), so this is a common, not exotic, referral.
Refer urgently for premenstrual suicidality
This one does not wait. PMDD carries a substantially elevated risk of suicidal ideation and attempts, and the cyclical timing can make the risk easy to under-weight (Osborn et al.). Ask directly about premenstrual suicidal thoughts. When they are present, escalate rather than route through a routine intake queue, and note the acuity so it can be prioritized.
If a patient is in crisis, direct her to call or text 988 (Suicide & Crisis Lifeline) or call 911.
Refer when the diagnosis is uncertain
Particularly when you cannot cleanly separate PMDD from a premenstrually exacerbated disorder. If the symptom picture is ambiguous — symptoms that may or may not clear between periods, a possible underlying depression, anxiety, or bipolar disorder — a psychiatric evaluation with prospective charting can resolve it. The distinction changes the treatment target, as covered in PMDD vs PME for providers. Sending the patient with charting already begun (see prospective symptom charting) makes that evaluation faster.
Refer when first-line management falls short
You do not have to have exhausted every option first, but a partial or absent response to first-line treatment is a clear referral point. If an SSRI or a first hormonal option has not controlled symptoms, a psychiatric prescriber can adjust dosing strategy (continuous versus luteal-phase), switch agents, or move to escalation options such as GnRH agonists with add-back therapy for severe or refractory disease (ACOG CPG No. 7). “The first thing didn’t fully work” is a reason to refer, not to stop.
How to refer to MCW
Mindful Counseling & Wellness provides telehealth psychiatric evaluation and medication management for adults across North Carolina, led by a board-certified psychiatric mental health nurse practitioner (PMHNP-BC) with a reproductive and perinatal mental health focus. The practice builds on any charting already underway and coordinates with the care you continue to provide, with patient consent.
To refer, call (919) 739-3808 or email — patient name and contact are enough to start, and no clinical records (and no patient health details by email) are needed. For the reproductive-mental-health context, see the perinatal mental health referral guide for NC providers; patients researching their own care can read the patient PMDD guide. If you have a patient who fits now, start a referral.
Sources
- ACOG Clinical Practice Guideline No. 7: Management of Premenstrual Disorders (2023) — SSRIs first-line; escalation options
- StatPearls (NCBI Bookshelf): PMDD — diagnosis, severity, first-line treatment
- Osborn et al. (PMC): PMDD and suicidality — systematic review and meta-analysis (elevated attempt and ideation risk)